Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
9.31 (1y: +33%)
Market Cap 1.07 B P/E(ttm)
Enterprise Value 967 M P/B 22.80
NKTR- NAS (USA)
Nektar Therapeutics, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$9.31
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry		 vs
history
Cash to Debt 2.029
NKTR's Cash to Debt is ranked lower than
71% of the 388 Companies
in the Global Biotechnology industry.

( Industry Median: 52.90 vs. NKTR: 2.029 )
NKTR' s 10-Year Cash to Debt Range
Min: 0.73   Max: 2.1
Current: 2.03
0.73
2.1
Equity to Asset -0.059
NKTR's Equity to Asset is ranked lower than
287356% of the 348 Companies
in the Global Biotechnology industry.

( Industry Median: 0.58 vs. NKTR: -0.059 )
NKTR' s 10-Year Equity to Asset Range
Min: -0.06   Max: 0.44
Current: -0.06
-0.06
0.44
F-Score: 3
Z-Score: -4.54
M-Score: -4.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry		 vs
history
Operating margin (%) -173.90
NKTR's Operating margin (%) is ranked lower than
675675% of the 148 Companies
in the Global Biotechnology industry.

( Industry Median: 13.90 vs. NKTR: -173.90 )
NKTR' s 10-Year Operating margin (%) Range
Min: -331.7   Max: -13.2
Current: -173.9
-331.7
-13.2
Net-margin (%) -211.7
NKTR's Net-margin (%) is ranked lower than
671140% of the 149 Companies
in the Global Biotechnology industry.

( Industry Median: 13.50 vs. NKTR: -211.7 )
NKTR' s 10-Year Net-margin (%) Range
Min: -322.7   Max: -12
Current: -211.7
-322.7
-12
ROE (%) -365.5
NKTR's ROE (%) is ranked lower than
689654% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 9.80 vs. NKTR: -365.5 )
NKTR' s 10-Year ROE (%) Range
Min: -365.5   Max: -15.3
Current: -365.5
-365.5
-15.3
ROA (%) -34.5
NKTR's ROA (%) is ranked lower than
675675% of the 148 Companies
in the Global Biotechnology industry.

( Industry Median: 6.70 vs. NKTR: -34.5 )
NKTR' s 10-Year ROA (%) Range
Min: -37.5   Max: -4.5
Current: -34.5
-37.5
-4.5
ROC (Joel Greenblatt) (%) -453.80
NKTR's ROC (Joel Greenblatt) (%) is ranked lower than
740740% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 21.60 vs. NKTR: -453.80 )
NKTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -453.8   Max: -44.3
Current: -453.8
-453.8
-44.3
Revenue Growth (%) -2.3
NKTR's Revenue Growth (%) is ranked lower than
714285% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 12.40 vs. NKTR: -2.3 )
NKTR' s 10-Year Revenue Growth (%) Range
Min: -24.7   Max: 19.4
Current: -2.3
-24.7
19.4
EBITDA Growth (%) 6
NKTR's EBITDA Growth (%) is ranked lower than
77% of the 99 Companies
in the Global Biotechnology industry.

( Industry Median: 11.00 vs. NKTR: 6 )
NKTR' s 10-Year EBITDA Growth (%) Range
Min: -40.1   Max: 13.2
Current: 6
-40.1
13.2
EPS Growth (%) 7.8
NKTR's EPS Growth (%) is ranked lower than
72% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 12.20 vs. NKTR: 7.8 )
NKTR' s 10-Year EPS Growth (%) Range
Min: -35.6   Max: 33.9
Current: 7.8
-35.6
33.9
ยป NKTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

NKTR Guru Trades in Q2 2012

PRIMECAP Management 9,116,656 sh (+0.09%)
Louis Moore Bacon 400,000 sh (unchged)
» More
Q3 2012

NKTR Guru Trades in Q3 2012

PRIMECAP Management 9,121,956 sh (+0.06%)
Louis Moore Bacon 150,000 sh (unchged)
» More
Q4 2012

NKTR Guru Trades in Q4 2012

PRIMECAP Management 6,469,856 sh (-29.07%)
» More
Q1 2013

NKTR Guru Trades in Q1 2013

PRIMECAP Management 7,052,004 sh (+9%)
» More
» Details

Insider Trades

Latest Guru Trades with NKTR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2012-12-31 Reduce -29.07%0.05%$5.99 - $10.83 $ 9.3115%6469856
Jean-Marie Eveillard 2011-12-31 Sold Out 0.003%$4.22 - $5.62 $ 9.3190%0
Jean-Marie Eveillard 2011-09-30 New Buy$4.98 - $7.65 $ 9.3156%125000
PRIMECAP Management 2011-03-31 Add 41.43%0.02%$8.58 - $12.85 $ 9.31-11%6128100
PRIMECAP Management 2010-06-30 Add 82.73%0.04%$11.25 - $15.58 $ 9.31-30%3579750
PRIMECAP Management 2010-03-31 Add 106.54%0.03%$9.15 - $15.52 $ 9.31-26%1959000
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 22.80
NKTR's P/B is ranked lower than
93% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. NKTR: 22.80 )
NKTR' s 10-Year P/B Range
Min: 1.05   Max: 22.83
Current: 22.8
1.05
22.83
P/S 12.41
NKTR's P/S is ranked lower than
60% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 7.53 vs. NKTR: 12.41 )
NKTR' s 10-Year P/S Range
Min: 1.76   Max: 48.02
Current: 12.41
1.76
48.02
EV-to-EBIT 0.1
NKTR's EV-to-EBIT is ranked lower than
375939% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. NKTR: 0.1 )
NKTR' s 10-Year EV-to-EBIT Range
Min: 8.5   Max: 685.7
Current: 0.1
8.5
685.7

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 93.1
NKTR's Price/Net Current Asset Value is ranked lower than
73% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. NKTR: 93.1 )
NKTR' s 10-Year Price/Net Current Asset Value Range
Min: 28   Max: 265
Current: 93.1
28
265
Price/Median PS Value 1.3
NKTR's Price/Median PS Value is ranked lower than
65% of the 346 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NKTR: 1.3 )
NKTR' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 4.4
Current: 1.3
0.2
4.4
Earnings Yield (Greenblatt) 991.50
NKTR's Earnings Yield (Greenblatt) is ranked lower than
446428% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NKTR: 991.50 )
NKTR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 999.1
Current: 991.5
0.1
999.1
Forward Rate of Return (Yacktman) -4.65
NKTR's Forward Rate of Return (Yacktman) is ranked lower than
1492536% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. NKTR: -4.65 )
NKTR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -38   Max: -26.1
Current: -4.65
-38
-26.1

Business Description

Nektar Therapeutics, Inc was incorporated in California in 1990 and reincorporated in Delaware in 1998. Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its current proprietary pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Its research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. The Company creates its innovative drug candidates by using its proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of drugs to create new molecular entities. The Company's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. It's most advanced proprietary drug candidate, NKTR-118, is an oral peripherally-acting opioid antagonist, currently in Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain. OIC is a common side effect of prescription opioids when used for chronic pain management. In September 2009, the Company entered into a global license agreement with AstraZeneca AB for the global development and commercialization of NKTR-118 and NKTR-119. NKTR-119 is an early stage research and development program that is designed to combine various opioids with NKTR-118. AstraZeneca is responsible for all clinical, regulatory and commercialization costs for NKTR-118 and NKTR-119. The Company has several proprietary pre-clinical and clinical drug candidates that are in the pain therapeutic area. NKTR-181 is an orally-available mu-opioid analgesic molecule with a long-acting profile to treat chronic pain that has been designed with the objective of addressing serious CNS-related side effects associated with standard opioid therapies. The Company frequently competes with pharmaceutical companies and other institutions. As a manufacturer of PEG reagents for the U.S. market, the Company is subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:ITH.Germany
ยป More Articles for NKTR

Headlines

Articles On GuruFocus.com
Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) May 06 2010 
Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year Jan 06 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 05 2009 
Nektar Therapeutics Reports Operating Results (10-Q) Aug 05 2009 

More From Our Partners
Data on AstraZeneca's Naloxegol - Analyst Blog May 23 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial